The US biotech industry is one big, convoluted mess. Patents are...

  1. 999 Posts.
    lightbulb Created with Sketch. 25
    The US biotech industry is one big, convoluted mess. Patents are only given for 10 years at the most, and when the product is a few years off patent, the generics and competitors swoop in like vultures.

    In the US, you can get a product up and running and produce sales despite a patent still existing. The onus is then essentially put on the original company to sue and stop the new company selling the product.

    This is happening more and more with aggressive generic products (see Mayne Pharma), and now seems to be happening in the testosterone replacement industry.

    Anyway, the other issue is the lawsuit (possibly multiple) regarding poor labeling in regards to the risks associated with the product. If you guys take the time to check out Axiron's website, you'll notice there is an entire page of warnings! The product is still incredably popular despite the risks that are associated with it. It appears older men are happy to try anything that will give them a boost.

    Also, the scenario is very similar to viagra when that first came around - years of skeptics and health warnings, however the product is still popular and part of mainstream society.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.9¢
Change
0.000(0.00%)
Mkt cap ! $7.747M
Open High Low Value Volume
1.9¢ 1.9¢ 1.9¢ $5.562K 292.7K

Buyers (Bids)

No. Vol. Price($)
4 381825 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 60000 2
View Market Depth
Last trade - 15.04pm 20/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.